(Q44124156)

English

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Eduardo Díaz-Rubio

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Jose Luis Gonzalez Larriba

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

Joaquim Bellmunt

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Joan Albanell

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Luis Paz-Ares

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Miguel A Climent

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Juan J de la Cruz

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Vicente Guillem

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Hernan Cortés-Funes

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

José Baselga

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Spanish Oncology Genitourinary Group

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

95

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

751-757

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12209718%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

21 January 2018

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10762

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44124156&oldid=2106831939"